DICE Therapeutics, Inc. Stock: price and insider trades · United States

DICE Therapeutics, Inc. was a U.S.-based biopharmaceutical company focused on discovering and developing novel oral therapies for inflammatory and immunology diseases. Before being acquired, it was listed on the NASDAQ and headquartered in South San Francisco, California, a core biotechnology cluster in the United States. The company evolved from DiCE Molecules Holdings, LLC into DICE Therapeutics, Inc. in connection with its IPO, and its business was built around a proprietary discovery engine called DELSCAPE, designed to identify selective oral small molecules capable of modulating protein-protein interactions with biologic-like potency. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000095017023008119/dice-20221231.htm?utm_source=openai))

From an operating perspective, DICE was a clinical-stage biotech rather than a commercial-stage pharmaceutical company. It did not have approved products or product revenue at the time it operated independently. Its lead strategic focus was on oral IL-17 inhibitors, an important validated target in immunology. That positioning was commercially attractive because the company was trying to address a major market need: offering oral alternatives to injectable biologics, potentially improving convenience, adherence, and patient access. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1645569/000156459021056499/dice-10q_20210930.htm?utm_source=openai))